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ABSTRACT
Background: Nonmotor symptoms (NMS) have a great impact on patients with Parkinson disease
(PD). The Non-Motor Symptoms Scale (NMSS) is an instrument specifically designed for the com-
prehensive assessment of NMS in patients with PD. NMSS psychometric properties have been
tested in this study.
Methods: Data were collected in 12 centers across 10 countries in America, Asia, and Europe. In
addition to the NMSS, the following measures were applied: Scales for Outcomes in Parkinson’s
Disease (SCOPA)-Motor, SCOPA-Psychiatric Complications (SCOPA-PC), SCOPA-Cognition,
Hoehn and Yahr Staging (HY), Clinical Impression of Severity Index for Parkinson’s Disease (CISI-
PD), SCOPA-Autonomic, Parkinson’s Disease Sleep Scale (PDSS), Parkinson’s Disease Question-
naire–39 items (PDQ-39), and EuroQol–5 dimensions (EQ-5D). NMSS acceptability, reliability,
validity, and precision were analyzed.
Results: Four hundred eleven patients with PD, 61.3% men, were recruited. The mean age was
64.5 9.9 years, and mean disease duration was 8.1 5.7 years. The NMSS score was 57.1
44.0 points. The scale was free of floor or ceiling effects. For domains, the Cronbach  coefficient
ranged from 0.44 to 0.85. The intraclass correlation coefficient (0.90 for the total score, 0.67–
0.91 for domains) and Lin concordance coefficient (0.88) suggested satisfactory reproducibility.
The NMSS total score correlated significantly with SCOPA-Autonomic, PDQ-39, and EQ-5D (rS
0.57–0.70). Association was close between NMSS domains and the corresponding SCOPA–
Autonomic domains (rS  0.51–0.65) and also with scales measuring related constructs (PDSS,
SCOPA-PC) (all p  0.0001). The NMSS total score was higher for women (p  0.02) and for
increasing disease duration, HY, and CISI-PD severity level (p 0.001). The SEM was 13.91 for
total score and 1.71 to 4.73 for domains.
Conclusion: The Non-Motor Symptoms Scale is an acceptable, reproducible, valid, and precise
assessment instrument for nonmotor symptoms in Parkinson disease. Neurology® 2009;73:
1584–1591
GLOSSARY
CCC  concordance correlation coefficient; CISI-PD  Clinical Impression of Severity Index for Parkinson’s Disease;
EQ-5D  EuroQol–5 dimensions; HRQL  health-related quality of life; HY  Hoehn and Yahr Staging; ICC  intraclass
correlation coefficient; IRB  institutional review board; MDS-UPDRS Movement Disorder Society–sponsored revision of
the Unified Parkinson’s Disease Rating Scale; NMS  nonmotor symptoms; NMSQuest  Non-Motor Symptoms Question-
naire; NMSS  Non-Motor Symptoms Scale; PD  Parkinson disease; PDQ-39  Parkinson’s Disease Questionnaire–39
items; PDSS  Parkinson’s Disease Sleep Scale; SCOPA  Scales for Outcomes in Parkinson’s Disease; SCOPA-AUT 
Scales for Outcomes in Parkinson’s Disease–Autonomic; SCOPA-COG  Scales for Outcomes in Parkinson’s Disease–
Cognition; SCOPA-M  Scales for Outcomes in Parkinson’s Disease–Motor; SCOPA-PC  Scales for Outcomes in Parkin-
son’s Disease–Psychiatric Complications; SEM  standard error of measurement; UPDRS  Unified Parkinson’s Disease
Rating Scale; VAS visual analog scale.
Nonmotor symptoms (NMS) are common in Parkinson disease (PD). Studies have found a
prevalence ranging from 21% at the diagnosis of PD1 to 88% after 7 years of disease duration.2
In a large international sample, the average number of declared NMS was more than 10
symptoms, and less than 2% of patients did not experience any of the explored NMS.3
NMS include autonomic dysfunction, mood disorders, fatigue, sleep disturbances, and neuro-
psychiatric symptoms. Patients experience an increasing number of NMS as the disease progresses,
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but some of these symptoms (olfactory prob-
lems, constipation, depression, and REM be-
havior disorder) may be present in the premotor
phase of the disease.4 These NMS may contrib-
ute to identify the population at risk and help in
the early detection of PD, but they may lead also
to misdiagnosis.1
NMS have a great impact on patients’ quality
of life and psychosocial functioning, and they
cause institutionalization and increasing costs of
care.4 Nevertheless, more than 50% of existing
NMS may be neglected in clinical practice,4,5 a
fact that can be explained, in part, by the lack of
comprehensive and valid specific instruments to
identify and assess NMS. Before 2006, several
rating scales were used to assess some NMS, but
there were no practical and reliable instruments
for evaluating the whole range of NMS. Two
instruments have been recently developed to ad-
dress this unmet need: the Non-Motor Sy-
mptoms Questionnaire (NMSQuest),6 for
screening purposes, and the Non-Motor Symp-
toms Scale (NMSS),7 for NMS assessment.
Both tools, NMSQuest and NMSS, have been
object of pilot studies by the PD NMS Group,
an academic organization.
The objective of the present study is to
test the NMSS7 in a multicenter interna-
tional setting to confirm and expand the
information available about the NMSS psy-
chometric attributes.
METHODS Design. This was an international, multicenter,
cross-sectional study with retest.
Sample. Consecutive patients with PD, older than 30 years at
onset of PD and at any stage of disease, diagnosed by a neurologist
with competence in movement disorders according to UK PD
Brain Bank criteria,8 participated in the study. Exclusion criteria
were the inability to read, understand, or answer written question-
naires, and the presence of comorbidity, sequelae, or any disorder
that interferes with or impedes assessment of PD manifestations.
Patients were recruited in 12 centers across 10 countries—
Brazil, India, Italy, Japan, The Netherlands, Romania, Spain,
United Kingdom, United States, and Venezuela—from Novem-
ber 2007 to September 2008.
Standard protocol approvals, registrations, and patient con-
sents. The study was approved by the Carlos III Institute of
Health institutional review board (IRB) and by local IRBs. Pa-
tients gave their informed consent before their participation in
the study.
Assessments. In addition to sociodemographic and historic
data, the following instruments were applied:
Neurologist-based. Scales for Outcomes in Parkinson’s
Disease–Motor (SCOPA-M),9 SCOPA–Psychiatric Complications
(SCOPA-PC),10 SCOPA–Cognition (SCOPA-COG),11 Hoehn
and Yahr Staging (HY),12 Clinical Impression of Severity Index for
Parkinson’s Disease (CISI-PD; a global clinical impression of sever-
ity),13 and the NMSS.7
Patient self-assessments. SCOPA–Autonomic (SCOPA-
AUT),14 Parkinson’s Disease Sleep Scale (PDSS),15 and Euro-
Qol–5 dimensions (EQ-5D)16 and Parkinson’s Disease
Questionnaire–39 items (PDQ-39),17 for health-related quality
of life (HRQL) assessment.
These assessments were chosen to examine areas not ex-
plored in the pilot study7 or to offer alternative information (e.g.,
SCOPA-M instead of Unified Parkinson’s Disease Rating Scale
[UPDRS]). A balance between observer-rated and self-
assessments, minimizing administrative and respondent burden,
was sought.
The NMSS is a specific scale developed to assess MNS in PD
over the past month. It is composed of 9 domains: cardiovascular
(2 items), sleep/fatigue (4 items), mood/apathy (6 items), per-
ceptual problems/hallucinations (3 items), attention/memory (3
items), gastrointestinal tract (3 items), urinary (3 items), sexual
function (2 items), and miscellaneous (4 items). Items are scored
for severity (from 0 to 3) and frequency (from 1 to 4), to capture
symptoms that are severe but relatively infrequent or that are less
severe but persistent. The theoretical maximum total score is 360
points.
For all rating scales except SCOPA-COG, PDSS, and EQ
visual analog scale (VAS), higher scores reflect higher severity in
the construct being measured. All scales were cross-culturally
adapted, if needed, following a protocol for translation, back-
translation, and consensus by bilingual persons, and participa-
tion of experts and patients when appropriate.
To evaluate the stability of the NMSS (test-retest reliability),
a group of patients in each participant center (n 10) repeated
the NMSS and CISI-PD assessment 1 to 2 weeks after the first
evaluation. In patients with fluctuations, the assessments were
performed during “on” state.
Data analysis. Data were analyzed at the National Center of
Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Because data did not fit normal distribution, nonparametric sta-
tistics were used. In addition to descriptive statistics, the follow-
ing NMSS psychometric properties were explored.
Acceptability. Quality of data were considered satisfactory if
more than 95% of NMSS data were fully computable. The range
of scores, the difference between mean and median (arbitrary
limit, 10% of the maximum possible score), the floor and ceiling
effect (maximum acceptable for both, 15%),18 and the skewness
(limits, 1 to  1) were calculated.
Reliability. Internal consistency was tested by the Cronbach
 coefficient (criterion value, 0.70), item-total correlation
(corrected for overlap; criterion value, rS 0.30), and item ho-
mogeneity (criterion value, 0.30). The intraclass correlation
coefficient (ICC, 2-way random effects model) was used to de-
termine the test-retest reliability of NMSS. The Lin concordance
correlation coefficient (CCC) was also calculated for the total
NMSS.19,20 ICC and CCC values 0.70 were considered satis-
factory.21 Standard values for acceptability and reliability were
according to previous studies.7,22,23
Construct validity. For convergent validity, a strong rela-
tionship (rS 0.50)24,25 was hypothesized between NMSS and
SCOPA-AUT (for total scores and corresponding subscales)
and, according to previous results,7 between NMSS total score
and HRQL measures (PDQ-39 and EQ-5D). Low to moderate
association (rS 0.50) was predicted for NMSS and other PD-
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related instruments. Internal validity was determined on the
basis of intercorrelations of NMSS domains (standard, rS 
0.30–0.70).26 Known-groups validity was explored for grouping
of patients by disease duration (5 years, 5–9 years,10 years),
age at onset (50 years, 51–65 years, 65 years), disease stage
(HY), and disease severity levels based on CISI-PD scores.27 At
this aim, Mann-Whitney and Kruskal-Wallis tests were used to
compare groups.
Precision for each NMSS domain and total score was esti-
mated by means of the standard error of measurement (SEM 
SD  [1  rxx]).22,28 An SEM value 1⁄2 SD was used as
criterion for precision, and both SEM and 1⁄2 SD were used as
estimates of minimally detectable change.29
RESULTS In the study, 411 patients with PD were
included (median 40 per center, range 20 – 60).
Mean age (SD) was 64.5  9.9 (range 34–89)
years, and they were predominantly men (61.3%),
married (75.4%) or widowed (10%), retired (56.4%)
or employee (25.3%), with 10.9  4.4 years of edu-
cation. The age at onset of PD was 56.4  10.3
years, the duration of disease was 8.1  5.7 years,
and the HY distribution was as follows: stage 1,
15.1%; stage 2, 40.4%; stage 3, 32.1%; stage 4,
10.5%; and stage 5, 1.7%. More than two-thirds of
the sample (68.6%) were treated with a combination
of antiparkinsonian drugs, whereas 28.5% were in
monotherapy (levodopa, 16.6%; dopamine agonist,
8.8%; other, 3.1%) and 2.9% were drug naive.
Descriptive statistics of the applied measures are
shown in table 1. NMSS data were fully computable
for 99.5% of the sample. The NMSS total mean
score was 57.1  44.0 (median  43, difference
mean  median  14.1 points, 3.9% and 6.1% of
the maximum theoretical and observed score; table
2). The difference between NMSS scores from
English-speaking and non–English-speaking coun-
tries was not significant. The NMSS total score was
higher for women (64.5  48.6) than for men
(52.4  40.3) (p  0.02). Two patients (0.50%)
declared no NMS, whereas 1 patient (0.24%)
reached the maximum score in the study (233
points). Regarding NMSS domains, all of them
showed a floor effect, and 2 (perceptual problems/
hallucinations and miscellaneous) did not cover the
full possible range of scores (table 2). Skewness was
1.2 for the total score.
Cronbach  coefficients ranged from 0.44 (mis-
cellaneous) to 0.85 (mood/apathy) (table 3). Item-
total correlation reached values from 0.20 to 0.73
(table 3), and item homogeneity reached values from
0.16 (miscellaneous) to 0.54 (attention/memory).
Regarding test-retest reliability (n  127), the ICC
for items reached values between 0.56 (item 15, dou-
ble vision) to 0.89 (item 10, seem sad or depressed).
For domains, the ICC ranged from 0.67 (sexual
function domain) to 0.91 (mood/apathy domain)
(table 3). The ICC was 0.90 and the CCC was 0.88
for the NMSS total score.
As hypothesized, the NMSS total score reached
the highest correlation coefficients with SCOPA-
AUT (rS  0.64), PDQ-39 (rS  0.70), and—at a
lower level—EQ-5D Index (rS  0.57). Correlation
coefficient values with other measures were as fol-
lows: HY, 0.38; SCOPA-M, 0.44; SCOPA-PC,
0.51; SCOPA-COG, 0.44; CISI-PD, 0.49; PDSS,
0.53; and EQ-VAS,0.37. NMSS domains showed
a tight relationship with measures for similar con-
structs: sleep/fatigue with PDSS (rS 0.56), percep-
tual problems/hallucinations with SCOPA-PC (rS
0.53), and attention/memory with CISI-PD cogni-
tion (rS  0.51). Just under the statistical threshold
for a high association was the correlation between
attention/memory and SCOPA-PC (rS  0.49).
Regarding the correlation between NMSS do-
mains and the corresponding SCOPA-AUT dimen-
sions, the following coefficient values were found:
cardiovascular, rS  0.62; gastrointestinal, rS 
0.65; urinary, rS  0.65; and sexual function, rS 
0.51. NMSS item 30 (excessive sweating) correlated
at a high level with the SCOPA-AUT thermoregula-
tory domain (rS  0.51). In addition, some NMSS
domains reached high correlations with the PDQ-
Table 1 Score distribution of the applied
rating scales
Mean SD Min Max
SCOPA-M 22.0 12.4 2 72
Motor examination 11.9 6.9 0 41
ADL 7.2 4.0 0 21
Motor complications 2.7 3.1 0 12
SCOPA-PC 1.9 2.5 0 16
SCOPA-COG 25.4 8.6 2 43
CISI-PD 8.5 4.8 1 24
Motor status 2.8 1.2 0 6
Disability 2.4 1.4 0 6
Motor complications 1.7 1.7 0 6
Cognitive status 1.6 1.4 0 6
SCOPA-AUT 18.0 10.4 0 51
PDSS 96.5 29.6 3 150
EQ-5D index 0.56 0.34 0.65 1
EQ-5D VAS 63.6 22.3 0 100
PDQ-39 28.7 17.5 0 87.3
Minminimum;Maxmaximum; SCOPAScales for Out-
comes in Parkinson’s Disease; M  Motor; ADL  activities
of daily living; PC Psychiatric Complications; COGCog-
nition; CISI-PD  Clinical Impression of Severity Index for
Parkinson’s Disease; AUT  Autonomic; PDSS  Parkin-
son’s Disease Sleep Scale; EQ-5D  EuroQoL–5 dimen-
sions; VAS  visual analog scale; PDQ-39  Parkinson’s
Disease Questionnaire–39 items.
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39: sleep/fatigue, 0.58; and mood/apathy, 0.57 (all
p  0.0001).
Regarding internal validity, 53% of the interdo-
main correlations were between 0.30 and 0.42, and
the rest were 0.30 (range: 0.06, perceptual prob-
lems/hallucinations with sexual function, to 0.42,
sleep/fatigue with miscellaneous).
The NMSS total score was higher for patients
with increased disease duration, HY stage, and
CISI-PD severity level (p  0.001; table 4). There
were no significant differences by age at onset.
SEM ranged from 1.71 (cardiovascular) to 4.73
(mood/apathy) for domains, and was 13.91 for total
score (table 5).
DISCUSSION The NMSS is an instrument specifi-
cally designed for the comprehensive measurement
of NMS in patients with PD. This study was aimed
to confirm and complete the information supplied
by the pilot study7 in a 70% wider sample of patients
and, for the most part (85%), applied by researchers
never before involved in NMSS development.
As a whole, NMSS acceptability was satisfactory.
Data quality was excellent, with 99.5% of data fully
computable and a difference between central ten-
dency statistics clearly10% of the maximum possi-
ble score. For 7 dimensions, the complete range of
scoring was covered; the total NMSS score was free
of a floor or ceiling effect; and the skewness value
(1.2) was slightly higher than the upper standard
limit (1.0). This asymmetry was consistent with
the floor effect present in all NMSS domains, a find-
ing already detected in the pilot study7 and in other
complex scales assessing NMS in PD.14 Such instru-
ments include a variety of symptoms grouped in di-
mensions, frequently unrelated to those included in
other domains and experienced only by a proportion
of the patients, so that the lower the prevalence of
symptoms is, the higher the domain floor effect is. In
this sense, findings are in agreement with prospective
studies that showed relatively lower prevalence for
hallucinations and perceptual problems (25%–60%)
than for sleep disorders and fatigue (40%–
98%),3,30-33 the NMSS dimensions reaching the
highest and lowest floor effect. Nonetheless, the
NMSS was developed as a unified assessment for a
diversity of NMS and, because of their high preva-
lence as a whole (only 0.50% of the patients declared
no NMS, as in the pilot study),7 its total score is
exempt of a floor effect.
Regarding internal consistency, 3 domains
(mood/apathy, attention/memory, and urinary)
reached coefficient values over the minimal threshold
for groups ( 0.70). The mean Cronbach  was
0.60, with the lowest values obtained for miscella-
Table 2 Data quality and acceptability of the Non-Motor Symptoms Scale
Fully
comput-
able,
% Mean SD Median Min Max
Floor
effect,
%
Ceiling
effect,
%
Item/domain
1. Light-headedness 100 1.4 2.4 0.0 0 12 59.4 1.0
2. Fainting 100 0.3 1.3 0.0 0 12 90.8 0.5
D1. Cardiovascular 100 1.8 3.2 0.0 0 24 57.9 0.2
3. Daytime sleepiness 100 2.0 2.9 0.0 0 12 52.6 2.9
4. Fatigue 100 3.5 3.9 2.0 0 12 34.1 8.8
5. Difficulty falling
asleep
100 2.7 3.8 1.0 0 12 49.6 8.5
6. Restless legs 99.8 1.4 2.7 0.0 0 12 68.0 1.5
D2. Sleep/Fatigue 99.8 9.6 9.0 7.0 0 48 13.2 0.2
7. Lost interest in
surroundings
100 1.5 2.7 0.0 0 12 65.7 1.9
8. Lackmotivation 100 1.9 3.2 0.0 0 12 56.4 4.4
9. Feel nervous 99.8 2.3 3.4 1.0 0 12 49.3 5.6
10. Seem sad 100 2.5 3.6 0.0 0 12 50.4 7.1
11. Flat mood 100 1.4 2.8 0.0 0 12 67.9 2.7
12. Difficulty
experiencing
pleasure
100 1.4 3.0 0.0 0 12 70.6 3.6
D3. Mood/Apathy 99.8 11.2 14.3 6.0 0 72 24.4 0.5
13. Hallucinations 100 0.6 1.9 0.0 0 12 82.5 1.0
14. Delusions 100 0.5 1.9 0.0 0 12 90.3 1.0
15. Double vision 100 0.7 2.1 0.0 0 12 82.5 1.5
D4. Perceptual problems/
Hallucinations
100 1.9 4.1 0.0 0 25 70.1 0.2
16. Concentration 100 2.3 3.1 1.0 0 12 46.0 3.2
17. Forget things or
events
100 2.0 2.9 1.0 0 12 49.1 2.9
18. Forget to do things 100 1.6 2.8 0.0 0 12 58.2 2.9
D5. Attention/Memory 100 5.8 7.3 3.0 0 36 28.0 0.2
19. Saliva 100 2.2 3.5 0.0 0 12 56.7 6.3
20. Swallowing 100 1.3 2.6 0.0 0 12 70.6 1.7
21. Constipation 100 2.9 4.0 0.0 0 12 50.9 9.7
D6. Gastrointestinal 100 6.3 7.3 4.0 0 36 26.5 0.5
22. Urgency 100 2.6 3.4 1.0 0 12 45.5 4.4
23. Frequency 100 2.8 3.6 1.0 0 12 45.5 5.8
24. Nocturia 100 3.6 3.8 2.0 0 12 31.6 10.0
D7. Urinary 100 9.0 8.7 7.0 0 36 17.8 1.2
25. Interest in sex 100 1.9 3.6 0.0 0 12 67.2 7.5
26. Problems having sex 100 1.8 3.5 0.0 0 12 72.0 6.3
D8. Sexual dysfunction 100 3.7 5.8 0.0 0 24 56.9 2.4
27. Pain 100 2.0 3.4 0.0 0 12 60.6 5.1
28. Taste or smell 100 2.6 3.8 0.0 0 12 58.4 7.3
29. Weight change 100 1.4 2.8 0.0 0 12 70.3 2.7
30. Excessive sweating 100 1.6 3.2 0.0 0 12 69.6 4.1
D9. Miscellaneous 100 7.6 8.1 5.0 0 37 24.1 0.2
NMSS total 99.5 57.1 44.0 43.0 0 233 0.5 0.2
Minminimum; Maxmaximum; NMSS Non-Motor Symptoms Scale.
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neous (0.44) and perceptual problems/hallucinations
(0.45) (table 3). However, 23 items (77%) showed
item-total correlation coefficients over the standard
0.30, and the item homogeneity was higher than
the standard value for cardiovascular, mood/apathy,
attention/memory, urinary, and sexual function. In-
ternal consistency reflects the precision of a scale,
“based on the homogeneity of the scale’s items at one
point in time.”23 The inclusion of few items for assess-
ment of some complex domains, such as perceptual
problems/hallucinations, allows for low intercorrelation
among the items and low  values (a coefficient influ-
enced by the number of items).25 However, the need for
obtaining a brief instrument for holistic evaluation of
the many NMS potentially present in PD dictated that
strategy.
Table 3 Reliability of the Non-Motor Symptoms Scale
Item-total correlation
(Cronbach )
Intraclass correlation
coefficient
Item/domain
1. Light-headedness, dizziness 0.43* 0.68
2. Fainting or blacking out 0.84
D1. Cardiovascular (0.53) 0.72
3. Fall asleep unintentionally 0.26 0.75
4. Fatigue or lack of energy 0.45 0.70
5. Difficulties falling/staying asleep 0.40 0.65
6. Restlessness in legs 0.34 0.62
D2. Sleep/Fatigue (0.58) 0.77
7. Loss of interest in surroundings 0.67 0.81
8. Loss of interest in doing things 0.68 0.77
9. Feel nervous, worried, frightened 0.55 0.70
10. Seem sad or depressed 0.65 0.89
11. Flat mood 0.56 0.70
12. Difficulty in experiencing pleasure 0.70 0.63
D3. Mood/Apathy (0.85) 0.91
13. Sees things that are not there 0.31 0.85
14. Beliefs that are not true 0.27 0.68
15. Double vision 0.25 0.56
D4. Perceptual problems/Hallucinations (0.45) 0.71
16. Problems sustaining concentration 0.53 0.65
17. Forget things or events 0.73 0.78
18. Forget to do things 0.59 0.67
D5. Attention/Memory (0.77) 0.83
19. Dribbling saliva 0.32 0.71
20. Difficulty swallowing 0.43 0.80
21. Constipation 0.22 0.79
D6. Gastrointestinal (0.49) 0.78
22. Difficulty holding urine 0.53 0.81
23. Frequently voiding 0.59 0.76
24. Nocturia 0.51 0.79
D7. Urinary (0.72) 0.83
25. Altered interest in sex 0.36* 0.69
26. Problems having sex 0.67
D8. Sexual function (0.52) 0.67
27. Unexplained pain 0.35 0.70
28. Change in ability to taste/smell 0.23 0.73
29. Change in weight 0.20 0.71
30. Excessive sweating 0.22 0.81
D9. Miscellaneous (0.44) 0.81
*Interitem correlation.
Table 4 Known-groups validity of theNon-Motor
SymptomsScale
Mean SEM 95%CI
Hoehn and Yahr
stage
I 34.3 3.3 27.8–40.7
II 49.1 3.0 43.1–55.1
III 61.9 3.7 54.6–69.2
IV 92.3 7.2 78.1–106.5
V 123.6 24.8 74.8–172.3
CISI-PD severity
level
Mild 41.8 2.5 36.8–46.8
Moderate 57.3 2.9 51.7–63.0
Severe 107.7 6.7 94.5–121.0
Disease duration
<5 y 45.8 3.5 38.9–52.8
5–9 y 55.5 3.5 48.6–62.4
>10 y 69.4 4.0 61.5–77.2
All Kruskal-Wallis test, all p 0.0001.
SEM standard error of the mean; CI confidence inter-
val; CISI-PD  Clinical Impression of Severity Index for
Parkinson’s Disease.
Table 5 Non-Motor Symptoms Scale precision
andminimally detectable change
Range of
scores SEM SD
Cardiovascular 0–24 1.71 1.61
Sleep/Fatigue 0–48 4.31 4.50
Mood/Apathy 0–72 4.28 7.14
Perceptual
problems/Hallucinations
0–36 2.19 2.03
Attention/Memory 0–36 3.02 3.66
Gastrointestinal 0–36 3.40 3.62
Urinary 0–36 3.60 4.36
Sexual function 0–24 3.35 2.92
Miscellaneous 0–48 3.62 4.05
NMSS total score 0–360 13.91 22.00
SEM  standard error of measurement; NMSS  Non-
Motor Symptoms Scale.
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In this study, internal consistency results were
marginally lower than in the pilot study,7 a difference
probably related to the conditions of the present
study. The participant field researchers were not fa-
miliar with the scale, and they received the protocol
and material for the study via e-mail, without addi-
tional instructions or investigators meeting. These
circumstances were intentional, to test the measure
apart of any potential “favorable” bias introduced by
the scale developers.
Regarding the reproducibility of the NMSS, 67%
of the items and all the domains except sexual func-
tion reached ICC values at the standard level of 0.70
or higher (table 3). Again, these results are similar to
the corresponding findings in the pilot study.7 In ad-
dition, the ICC for the total score was calculated in
the present study, and, to overcome some problems
with the ICC assumptions (common population
variance for the different measures),20 the Lin con-
cordance coefficient was also obtained.19 Both coeffi-
cients (0.90 and 0.88) showed that NMSS total score
possesses a satisfactory stability.
The construct validity analysis of the NMSS
showed evidence favoring an appropriate interpreta-
tion of NMSS scores based on the theoretical impli-
cations associated with the construct. The
convergent validity with scales measuring related
constructs was moderate or high, mainly with the
specific HRQL questionnaire (PDQ-39) and
SCOPA-AUT. The NMSS components have been
identified in a diversity of studies as sources of dis-
tress and quality of life deterioration in PD.34-37
Therefore, a close association between NMSS and
PDQ-39 scores was expected, as anticipated with the
PDQ-8 in the pilot study.7 On the other hand, 4
domains of the NMSS overlap with the SCOPA-
AUT domains (cardiovascular, gastrointestinal, uri-
nary, and sexual function), and the correlation
coefficients between the corresponding components
were high (rS  0.51–0.65), as it was between the
total scores (rS 0.64). To be highlighted is the high
association found between some NMSS subscales
and specific measures for similar constructs: sleep/
fatigue with PDSS, perceptual problems/hallucina-
tions with SCOPA-PC, and attention/memory with
CISI-PD cognition (rS  0.51–0.56). In summary,
the convergent validity of the NMSS was satisfactory
in the present study.
The NMSS demonstrated the ability to detect dif-
ferences, at a point in time, among groups of pa-
tients. As per the results in the present study, NMSS
scores are higher for increasing PD duration, HY
stage, and severity level based on the CISI-PD (table
4). A proper discriminative validity was observed in
the pilot study for severity levels based on HY,7 and
that result is now confirmed and expanded. Al-
though correlation of NMSS (domains and total
score) was associated at a low or moderate level with
duration of disease, HY, and total CISI-PD, the anal-
ysis by groups showed that NMS increased in preva-
lence and severity with the progression of PD.3,7
The SEM represents the error associated with the
measurement and remains relatively constant across
samples,22,23,38 although a variation depending on
the method (reliability coefficient applied) and the
scores’ variance in the sample may be observed.28 The
SEM is also considered the minimally detectable
change28,29,38 and, therefore, furnishes an estimate of
the scale responsiveness.28 Six of the 9 NMSS do-
mains showed SEM values less than 10% of their
maximum theoretical score and/or less than 1⁄2 SD,
whereas the rest were higher. The SEM of the NMSS
total score also was 8.10 points lower than the corre-
sponding 1⁄2 SD (table 5). The obtained values were
close to those of the pilot study,7 except for the
NMSS total score SEM, which was almost double in
the present study. This discrepancy may be explained
by the very high reliability index (ICC  0.97) ob-
tained from an insufficient number of patients in-
cluded in the test-retest analysis of the pilot study
(n  30),21 recognized as a limitation of the study.7
Taking into consideration the results of the present
study, it may be concluded that NMSS is a precise
and potentially responsive measure.
Limitations of the present study are related to the
aforementioned organizational aspects, without extra
instructions or training with the scale. However, this
strategy was chosen to simulate a scenario whereby
real-life use of the scales are replicated, avoiding a
potentially artificial and favorable use for a validation
study. An additional limitation is depending on the
sample and related to the low representation of pa-
tients in the most advanced stages of disease. A high
proportion of patients in that situation will fit with
the exclusion criteria for this kind of study, this way
retaining a gap in knowledge about NMS assessment
in those patients. On the other hand, all the prob-
lems associated with summative scales39 are operative
with the NMSS total score, which—at any rate—
may represent the burden of NMS.
The most relevant NMS are also covered by the
Movement Disorder Society–sponsored revision of
the UPDRS (MDS-UPDRS), each symptom being
represented by 1 item with 5 options of response.
Therefore, the information it provides on severity is
limited.40 The NMS Scale includes 2 to 6 items per
domain, each item scoring severity and frequency
(0–12 points), this way providing a more detailed
assessment. Furthermore, some relevant NMS not
mentioned in the MDS-UPDRS are addressed in the
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NMS Scale. Prevalence studies have shown that these
NMS, such as sexual dysfunction, visual problems,
and sweating, are important items for a holistic as-
sessment of PD.
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